Data suggest technology provides improved delayed-release profile that ensures adrulipase is delivered to targeted areas of the GI tract
First Wave BioPharma expects to initiate Phase 2 trial investigating “optimized adrulipase” prior to year-end 2022
https://finance.yahoo.com/news/first-wave-biopharma-finalizes-selection-110000702.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.